The K65R mutation: Selection, frequency, and possible consequences

AIDS Reader

Volumn 14, Issue 11, 2004, Pages

  Moyle, Graeme J ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Drug resistance; HIV AIDS; Mutations

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; ZALCITABINE;

COMBINATION CHEMOTHERAPY; DRUG SENSITIVITY; GENE FREQUENCY; GENE MUTATION; GENETIC RESISTANCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MONOTHERAPY; MULTIDRUG RESISTANCE; POINT MUTATION; REVIEW; STRUCTURAL GENE; TREATMENT FAILURE; TURNOVER TIME; VIRUS LOAD; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; MUTATION;

EID: 19944427117     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-122.
2. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
3. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995;69:5087-5094.
4. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483-489.
5. Götte M, Arion D, Parnaik MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol. 2000;74:3579-3585.
6. Mohri H, Singh MK, Ching WT, Ho DD. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc Natl Acad Sci U S A. 1993;90:25-29.
7. Nájera I, Richman DD, Olivares I, et al. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses. 1994;10:1479-1488.
8. Nájera I, Holguín A, Quiñones-Mateu E, et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol. 1995;69:23-31.
9. de Jong MD, Schuurman R, Lange JM, Boucher CA. Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective pressure. Antivir Ther. 1996;1:33-41.
10. Cleland A, Watson HG, Robertson P, et al. Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus iype 1-infecied patients. J Acquir Immune Defic Syndr Hum Retroviral. 1996;12:6-18.
11. Craig JC, Moyle GJ. The development of resistance of HIV-1 to zalcitabine. AIDS. 1997;11:271-279.
12. Winston A, Mandalia S, Pillay O, et al. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients. AIDS. 2002;16:2087-2089.
13. Winston A, Pozniak A, Mandalia S, et al. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS. 2004;18:949-951.
14. Staszewski S, Dauer B, Stuermer M, et al. Predictors of loss of virologic response to tenofovir DF (TDF) therapy in HIV-1+ patients. Presented at the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract WePeB5713.
15. Bae AS, Waters JM, Margot NA, et al. Pre-existing L74V is a risk factor for virological non-response and development of K65R in patients taking tenofovir DF (TDF). Antivir Ther. 2004;9:S174. Abstract 158.
16. Winters MA, Shafer RW, Jellinger RA, et al. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother. 1997;41:757-762.
17. Larder BA, Kohli A, Bloor S, et al. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxyinosine or AZT plus 2′,3′-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group. J Virol. 1996;70:5922-5929.
18. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA. 2004;292:180-189.
19. Roge B, Barfod T, Kirk O, et al. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. HIV Med. 2004;5:344-351.
20. Harrigan PR, Stone C, Griffin P, et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J Infect Dis. 2000;181:912-920.
21. Moyle G. Resistance and cross-resistance to abacavir. HIV Med. 2001;2:154-162.
22. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
23. Podzamczer D, Ferrer E, Gatell JM, et al. Early virological failure and occurrence of resistance in naive patients receiving tenofovir, didanosine and efavirenz. Antivir Ther. 2004;9:S172. Abstract 156.
24. 3 receiving ddI/tenofovir/efavirenz as initial therapy: results from a randomised comparative trial. Presented at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Abstract H-566.
25. Molina JM, Gathe J, Lim PL, et al. Comprehensive resistance testing in antiretroviral naive patients treated with once-daily lopinavir/ritonavir plus tenofovir and emtricitabine: 48-week results from study 418. Presented at the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract WePeB5701 (poster).
26. Macmanus S, Yates P, White S, et al. GW433908 in ART-naive subjects: absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 598.
27. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. Presented at the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco. Abstract 51.
28. Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failure in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus Study. Presented at the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco. Abstract 52.
29. Gallant JE, Rodriguez AE, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago. Abstract H-H-1722a.
30. Ait-Khaled M, Rakik A, Griffin P, et al. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudirte in HIV-1-infected adults with no prior antiretroviral therapy. Antivir Ther. 2002;7:43-51.
31. Melby T, Tortell S, Thorborn D, et al. Comparison of viral resistance emerging over 48 weeks of therapy with IDV/COM vs ABC/COM (CNA3005). Presented at the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco. Abstract 750.
32. Elion R, Cohen C, DeJesus E, et al. COL40263: resistance and efficacy of once-daily Trizivir and tenofovir DF in antiretroviral-naive subjects. Presented at the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco. Abstract 53.
33. Miller MD. K65R, TAMs and tenofovir. AIDS Rev. 2004;6:22-33.
34. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991;253:1557-1559.
35. Goldschmidt V, Marquet R. Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Inf J Biochem Cell Biol. 2004;36:1687-1705.
36. Srinivas RV, Fridland A. Antiviral activities of 9-R-2- phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob Agents Chemother. 1998;42:1484-1487.
37. Miller MD, White KL, Petropoulos CJ, Parkin NT. Decreased replication capacity of HIV-1 clinical isolates containing K65R or M184V RT mutations. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 616.
38. Deval J, Navarro JM, Selmi B, et al. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J Biol Chem. 2004;279:25489-25496.
39. Miller MD, Margot NA, McColl DJ, et al. Characterization of virologie failure through 96 weeks among treatment-naive patients taking tenofovir DF (TDF) or stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV). Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris; Poster 553.
40. DeJesus E, Herrera G, Teofilo E, et al. Efficacy and safety of abacavir versus zidovudine in antirerrovial therapy naive adults with HIV-1 infection (study CNA 30024). Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago. Abstract H-446.
41. Gazzard BG, DeJesus E, Cahn P, et al. Abacavir (ABC) once daily (OAD) plus lamivudine (3TC) OAD in combination with efavirenz (EFV) OAD is well-tolerated and effective in the treatment of antiretroviral therapy (ART) naive adults with HIV-1 infection (ZODIAC Study: CNA 30021). Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago. Abstract H-1722b.